Dupilumab safe to continue during vaccine administration in children with AD reveals study

Written By :  Aditi
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-03-20 13:30 GMT   |   Update On 2024-03-21 09:21 GMT

Dupilumab inhibits interleukin (IL)-4 and IL-13 signalling. This monoclonal antibody also acts as an immunomodulator. The current recommendation is to avoid live vaccine administration in dupilumab-treated patients.A case series involving nine children with severe atopic dermatitis (AD) receiving measles, mumps, and rubella (MMR) vaccine with/without the varicella vaccine in dupilumab...

Login or Register to read the full article

Dupilumab inhibits interleukin (IL)-4 and IL-13 signalling. This monoclonal antibody also acts as an immunomodulator. The current recommendation is to avoid live vaccine administration in dupilumab-treated patients.

A case series involving nine children with severe atopic dermatitis (AD) receiving measles, mumps, and rubella (MMR) vaccine with/without the varicella vaccine in dupilumab clinical trials found no emergence of side effects within four weeks after vaccination. Consequently, the researchers concluded that dupilumab is safe to continue during vaccine administration. This case report is published in Pediatric Dermatology.

In a phase 2/3 clinical trial of dupilumab involving 6-month to 5-year-old children ( subsequently participated in the LIBERTY AD PED-OLE) with moderate-to-severe atopic dermatitis, nine children (protocol deviation) received MMR vaccine with or without varicella vaccine. Five of these children received the vaccine with a ≤12-week gap after dupilumab administration, while four received it >12 weeks after discontinuing dupilumab.

Key findings from the study are:

  • Nine children had severe AD at baseline.
  • Five of the nine children received the MMR or MMR and varicella vaccines within a 1-7 week gap after their dupilumab administration, with treatment resuming for one child as early as two days and three children after 18-43 days.
  • No serious adverse events were reported during a post-vaccination period in any children.

Concluding further, they said, In this case, a series of nine children with severe AD who received the MMR vaccine with or without varicella vaccine while being treated with dupilumab, no adverse events or infection were reported within four weeks of vaccination. Further studies are needed to investigate safety and immune response to live attenuated vaccines in dupilumab-treated patients

Sanofi and Regeneron Pharmaceuticals Inc. sponsored the study.

Reference:

Siegfried et al. A case series of live attenuated vaccine administration in dupilumab‐treated children with atopic dermatitis. Pediatric Dermatology.


Tags:    
Article Source : Pediatric Dermatology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News